The restoration
of balance

Resolaris™

Background

We harness the power of the Resokine pathway and its association in skeletal muscle with homeostasis in the form of Resolaris™ – a potentially first-in-class therapeutic for patients with severe, rare myopathies with an immune component (RMIC).

We derived Resolaris from a naturally occurring protein, the histidine aminoacyl tRNA synthetase (HARS), which we believe possesses the potential to reset the immune system in diseased tissue to a more normal state in a non-immunosuppressive manner.

Resolaris: 1st in Class Protein Therapeutic Candidate

Harnessing the Resokine Pathway

Resolaris - 1st in class protein therapeutic candidate

Mechanisms of Action »

Preclinical »

Clinical Application »

© 2007 - 2017   aTyr Pharma.   Legal   Privacy Policy